Evidence map›Paper›PMID 25486196›Full record

ArticleCell cycle (Georgetown, Tex.)2014

A cancer-associated mutation inactivates a region of the high-mobility group protein HMG20b essential for cytokinesis.

MiYoung Lee, Ashok R Venkitaraman

Open access · hybridAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

MiYoung Leea University of Cambridge ; Medical Research Council Cancer Unit; Hutchison/MRC Research Center ; Cambridge , UK.
Ashok R Venkitaraman
University of Cambridge · GB

Funding

Medical Research Council G1001521Medical Research Council MC_U105359877Medical Research Council MC_UU_12022/1
6 · The paper itself

Abstract

Defects in the completion of cell division by cytokinesis have long been proposed to foster carcinogenesis by engendering chromosome instability, but few tumor suppressor mechanisms controlling this process have so far been identified. Here, we identify a carboxyl (C)-terminal region of the high-mobility group protein HMG20b that is essential for cytokinesis, and report that it is inactivated by a cancer-associated mutation. We find that a C-terminal region of HMG20b spanning residues 173-317 is necessary and sufficient not only for its localization to cytokinetic structures, but also for its interaction with the tumor suppressor BRCA2, implicated in the abscission step of cytokinesis. Indeed, expression of this C-terminal HMG20b region suffices to restore cytokinesis in HMG20b-depleted cells. The non-conservative substitution of HMG20b residue Ala247 with Pro, reported in human lung cancer, disrupts these activities of HMG20b, impairing cytokinesis in a trans-dominant manner. Our findings provide fresh insight into the mechanism by which the HMG20b-BRCA2 complex controls mitotic cell division, and implicate heterozygous HMG20b mutations affecting cytokinesis regulation in the genesis of human cancers.

Indexed as

MutationAlanineBRCA2 ProteinCytokinesisDNA-Binding ProteinsHeLa CellsHigh Mobility Group ProteinsHumansLung NeoplasmsProlineAlanineBRCA2 ProteinDNA-Binding ProteinsHigh Mobility Group ProteinsHMG20B protein, humanProlineA247P, alanine to proline substitution at position 247BRCA2BRCA2, breast cancer 2, early onsetCOSMIC, Catalogue of Somatic Mutations in CancercytokinesisDox, doxycyclineEGFP, enhanced green fluorescent proteinESCRT, endosomal sorting complex required for transportGST, glutathione S-transferaseHMG20bHMG, high mobility groupKLCC, kinesin-like coiled coilLuc, luciferasesomatic mutations in cancerTet, Tetracyclinetumor suppressionUTR, untranslated regionsV312G, valine to glycine substitution at position 312

Identifiers

PMID25486196
PMCPMC4614378
OpenAlexW2052997025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.